Advertisement

Will Adjuvant Chemotherapy Improve Outcome After Preoperative (Chemo) Radiotherapy? Still More Passion than Evidence

  • Peter Nygren
  • Bengt Glimelius
Chapter

Abstract

Recent data from randomised trials investigating the effect of adjuvant chemotherapy following (chemo)radiotherapy and surgery in rectal cancer are strictly interpreted negative. Thus, the default setting is to not recommend such treatment. However, based on meta- and subgroup analyses as well as incorporation of expert knowledge and experience in this field, it is reasonable to discuss adjuvant chemotherapy with patients having some defined characteristics and involve the patients in a shared decision-making. Studies ongoing will tell whether systemic chemotherapy in the neoadjuvant setting is a better approach.

References

  1. 1.
    Påhlman L, Bohe M, Cedermark B et al (2007) The Swedish rectal cancer registry. Br J Surg 94:1285–1292CrossRefPubMedGoogle Scholar
  2. 2.
    Glimelius B, Nygren P (2012) Will adjuvant chemotherapy improve outcome after preoperative chemoradiation? 22. In: Valentini V, Schmoll H-J, van de Velde CJH (eds) Multidisciplinary management of rectal cancer. Springer Science, Heidelberg. doi: 10.1007/978-3-642-25,005-7 Google Scholar
  3. 3.
    Petersen SH, Harling H, Kirkeby LT, Wille-Jorgensen P, Mocellin S (2012) Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Library 3:1–52Google Scholar
  4. 4.
    Bujko K, Glimelius B, Valentini V, Michalski W, Spalek M (2015) Postoperative chemotherapy in patients with rectal cancer receiving preoperative radio(chemo)therapy: a meta-analysis of randomized trials comparing surgery ± a fluoropyrimidine and surgery ± a fluoropyrimidine ± oxaliplatin. Eur J Surg Oncol 41:713–723CrossRefPubMedGoogle Scholar
  5. 5.
    Bosset JF, Calais G, Mineur L et al (2014) Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15:184–190CrossRefPubMedGoogle Scholar
  6. 6.
    Bosset JF, Collette L (2014) Adjuvant chemotherapy for rectal cancer – authors reply. Lancet Oncol 15:e197–e198CrossRefPubMedGoogle Scholar
  7. 7.
    Sainato A, Cernusco LNV, Valentini V et al (2014) No benefit of adjuvant fluorouracil leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol 113:223–229CrossRefPubMedGoogle Scholar
  8. 8.
    Glynne-Jones R, Counsell N, Quirke P et al (2014) Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (Xelox) versus control. Ann Oncol 25:1356–1362CrossRefPubMedGoogle Scholar
  9. 9.
    Breugom AJ, van Gijn W, Muller EW et al (2015) Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol 26:696–701CrossRefPubMedGoogle Scholar
  10. 10.
    Hong YS, Nam B-H, Kim K-P et al (2014) Oxaliplatin, fluorouracil and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 15:1245–1253CrossRefPubMedGoogle Scholar
  11. 11.
    Schmoll H-J, Haustermans K, Price T et al (2014) Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: disease-free survival results at interim analysis. J Clin Oncol 32:A3501Google Scholar
  12. 12.
    Rödel C, Graeven U, Fietkau R et al (2015) Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 16:979–989CrossRefPubMedGoogle Scholar
  13. 13.
    Nimeiri HS, Feng Y, Catalano PJ et al (2013) Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil and leucovorin versus oxaliplatin, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin for patients with stage II or III rectal cancer receiving either preoperative radiation and 5-fluorouracil or postoperative radiation and 5-fluorouracil: ECOG E3201 – an updated survival analysis. J Clin Oncol 31(A):e14711Google Scholar
  14. 14.
    Breugom AJ, Swets M, Bosset JF et al (2015) Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16:200–207CrossRefPubMedGoogle Scholar
  15. 15.
    Zekri J, Imtiaz S (2015) Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery in patients with rectal cancer: meta-analysis of all patients in 4 landmark trials. Radiother Oncol 114:413–414CrossRefPubMedGoogle Scholar
  16. 16.
    QUASAR, Collaborative, Group (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370:2020–2029CrossRefGoogle Scholar
  17. 17.
    Poulsen LO, Qvortrup C, Pfeiffer P et al (2015) Review of adjuvant chemotherapy for rectal cancer – why do treatment guidelines differ so much? Acta Oncol 54:437–446CrossRefPubMedGoogle Scholar
  18. 18.
    Maas M, Nelemans PJ, Valentini V et al (2015) Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3,313 patients. Int J Cancer 137:212–220CrossRefPubMedGoogle Scholar
  19. 19.
    Petrelli F, Coinu A, Lonati V, Barni S (2015) A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer. Int J Color Dis 30:447–457CrossRefGoogle Scholar
  20. 20.
    Dewdney A, Cunningham D, Tabernero J et al (2012) Neoadjuvant oxaliplatin, capecitabine and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (Expert-C). J Clin Oncol 30:1620–1627CrossRefPubMedGoogle Scholar
  21. 21.
    Landry JC, Feng Y, Prabhu RS et al (2015) Phase II trial of preoperative radiation with concurrent capecitabine, oxaliplatin and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) and bevacizumab in patients with locally advanced rectal cancer: 5-year clinical outcomes ECOG-ACRIN Cancer Research Group E3204. Oncologist 20:615–616CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Hong TS, Ryan DP (2015) Adjuvant chemotherapy for locally advanced rectal cancer: is it a given? J Clin Oncol 33:1878–1880CrossRefPubMedGoogle Scholar
  23. 23.
    Cervantes A, Glynne-Jones R (2015) Adjuvant chemotherapy for rectal cancer after preoperative radiation or chemoradiation: one size does not fit all. Ann Oncol 26:617–619CrossRefPubMedGoogle Scholar
  24. 24.
    Weiser MR, Zhang Z, Schrag D (2015) Locally advanced rectal cancer: time for precision therapeutics. Am Soc Clin Oocol Educ Book 2015:e192–e196CrossRefGoogle Scholar
  25. 25.
    Nilsson PJ, van Etten B, Hospers GAP et al (2013) Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancerv – the RAPIDO trial. BMC Cancer 13:279CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Glimelius B (2015) Adjuvant chemotherapy for patients with rectal cancer – will the controversy be solved? Acta Oncol 54:433–436CrossRefPubMedGoogle Scholar
  27. 27.
    Haynes AB, You N, Hu C-Y et al (2014) Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer. Cancer 120:1162–1170CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Orsini RG, Verhoeven RHA, Lemmens VEPP et al (2015) Comparable survival for young rectal cancer patients despite unfavourable morphology and more advanced-stage disease. Eur J Cancer 51:1675–1682CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2018

Authors and Affiliations

  1. 1.Department of Immunology, Genetics and PathologyUppsala UniversityUppsalaSweden

Personalised recommendations